Nitrosocarbonyl Release from *O*-Substituted Hydroxamic Acids with Pyrazolone Leaving Groups

Saghar Nourian, Robert P. Lesko, Daryl A. Guthrie, and John P. Toscano*

Department of Chemistry, 3400 North Charles Street, Johns Hopkins University, Baltimore, Maryland 21218, United States

This article is dedicated to Professor Gary H. Posner in appreciation of his career contributions to organic chemistry.

Abstract

A new class of nitrosocarbonyl precursors, *O*-substituted hydroxamic acids with pyrazolone leaving groups (OHPY), is described. These compounds generate nitrosocarbonyl intermediates, which upon hydrolysis release nitroxyl (azanone, HNO) under physiologically relevant conditions. Pyrazolones have been used to confirm the generation of nitrosocarbonyls by competitive trapping to form isomeric *N*-substituted hydroxamic acids (NHPY) via an *N*-selective nitrosocarbonyl aldol reaction. The rate of nitrosocarbonyl release from OHPY donors is impacted by donor substituents, including the pyrazolone leaving group.

Keywords: nitrosocarbonyl; nitroxyl; HNO; pyrazolone

* Corresponding author. Tel.: +1-410-516-6534; fax: +1-410-516-8420; e-mail: jtoscano@jhu.edu

1. Introduction

Nitroxyl (azanone, HNO), the one-electron reduced and protonated form of nitric oxide, has been shown to improve both vasorelaxation and myocardial contractility, making HNO donors ideal candidates for drug development.¹⁻⁹ HNO is a reactive molecule that spontaneously dimerizes to produce hyponitrous acid (HON=NOH), which then dehydrates to give nitrous oxide (N₂O).¹⁰ Due to this inherent reactivity, HNO must be generated *in situ* through the use of donor compounds.

Angeli's salt (Na₂N₂O₃, AS, Fig. 1) is a well-known donor that generates HNO under physiological conditions with a short half-life.¹¹ Derivatization of this inorganic salt has been unsuccessful to date, thus preventing modification for tunable HNO release. Piloty's acid (PA) derivatives and acyloxy nitroso compounds (AcON) represent other types of HNO donors that have been developed with tunable half-lives.¹²⁻¹⁷ Our group has recently reported two new series of HNO donors with half-lives that can be varied from minutes to hours under physiological conditions: (hydroxylamino)pyrazolone (HAPY) and (hydroxylamino)barbituric acid (HABA) derivatives.¹⁸⁻²⁰ In addition to these examples, the continued development of efficient HNO donors is important to expand the research tools available to understand the potential role of HNO in biological processes.

Fig. 1. Some previously reported HNO donors.

Another strategy to release HNO is based on the hydrolysis of nitrosocarbonyl intermediates.²¹⁻²² Nitrosocarbonyls are highly reactive species that can react with nucleophiles including water to generate HNO. Oxidation of hydroxamic acids and thermal decomposition of 9,10-dimethylanthracene adducts represent common approaches to nitrosocarbonyl generation.²³⁻²⁵ The photolysis of nitrodiazo compounds, nitronates with alpha leaving groups, and 1,2,4-oxadiazole-4-oxides have also been shown to generate nitrosocarbonyls efficiently.²⁶⁻²⁸ Recently, the aerobic oxidation of hydroxamic acids by metal catalysts under mild conditions has been developed as an efficient strategy for nitrosocarbonyl generation.²⁹⁻⁴⁶ In general, however, the above methods are not suitable for HNO generation under physiological conditions.

Herein, we report a novel class of nitrosocarbonyl donors that upon deprotonation and loss of the leaving group (Scheme 1, HX = pyrazolone) generate nitrosocarbonyl intermediates that can hydrolyze to release HNO under physiological conditions. As has been demonstrated in recent reports,^{33,35,36,40-42,45} nitrosocarbonyls can react with nucleophiles through an *N*-selective nitrosocarbonyl aldol reaction to produce *N*-substituted hydroxamic acid adducts. We have recently found that pyrazolones are efficient traps for nitrosocarbonyl intermediates to generate *N*-substituted hydroxamic acid derivatives with pyrazolone leaving groups (NHPY) in a reversible manner.⁴⁷ In the current work, we observe OHPY decomposition to generate nitrosocarbonyls which further react with pyrazolones to produce isomeric NHPY compounds (Scheme 1). We have synthesized and studied NHPY compounds independently, and have recently demonstrated the efficient formation of nitrosocarbonyl intermediates upon decomposition of these compounds.⁴⁷

Scheme 1. Reactivity of OHPY nitrosocarbonyl precursors

2. Results and Discussion

2.1. Synthesis

OHPY compounds **1** have been synthesized by formation of the corresponding bromide (Br-PY) followed by reaction with hydroxamic acids (Scheme 2). Initially, OHPY **1a** was synthesized without the need for chromatographic purification, and its structure was confirmed by X-ray crystallography (Supporting Information). The other precursors were purified using column chromatography.

Scheme 2. Synthesis of OHPY derivatives

The OHPY and NHPY isomers can obviously be distinguished by X-ray crystallography. An analysis of ^{13}C NMR data and available crystal structures (Supporting Information), reveal that OHPY and NHPY compounds have distinctive

chemical shifts for their quaternary carbons ($\delta = 87.6 - 90.2$ ppm for OHPY vs. $\delta = 68.4 - 76.5$ ppm for NHPY). Thus, ^{13}C NMR spectroscopy conveniently allows the two isomers to be distinguished if crystal structures cannot be obtained.

2.2. Decomposition of OHPY compounds

Nitrosocarbonyl formation following OHPY decomposition under physiological conditions was studied. As described above, the reaction of nitrosocarbonyls and pyrazolones to produce NHPY compounds can be efficient. Upon nitrosocarbonyl generation from OHPY precursors **1**, therefore, a competition exists between hydrolysis to generate HNO and carboxylic acid **4** (Scheme 3, *Path A*) and trapping by the pyrazolone byproduct **2** to produce NHPY compounds **3** (Scheme 3, *Path B*). NHPY compounds subsequently can also release nitrosocarbonyl intermediates with half-lives that depend on R^1 , R^2 , and R^3 (Scheme 3, *Path C*).⁴⁷

Scheme 3. Reactivity of OHPY donors **1**

¹H NMR spectroscopy was used to examine the decomposition of OHPY donors and measure relative product yields in aqueous solution (Table 1).^{19,20} Pyrazolone **2**, NHPY **3**, and carboxylic acid **4** are cleanly formed as the only observable organic products. Because NHPY compounds **3a**, **3c**, and **3d** all have half-lives on the order of days,⁴⁷ *Path C* in Scheme 3 does not contribute to the observed chemistry for OHPY donors **1a**, **1c**, and **1d**. Thus, the relative yields of pyrazolone **2** and carboxylic acid **4** compared with that for NHPY compound **3** in Table 1 reflect the competition between *Path A* and *Path B* for these donors.

Table 1. Product yields and half-lives for OHPY donors

OHPY	R ¹	R ²	R ³	% 2 ^a	% 3 ^a	% 4 ^a	<i>t</i> _{1/2} (min) ^b
1a	Ph	C(=NOMe)Me	Me	74	26	73	25
1b	Ph	Me	Me				Stable ^c
1c	Ph	C(=NOMe)Me	MeO	28	72	27	0.6
1d	Me	C(=NOMe)Me	MeO	14	86	14	1.2
1e	Ph	C(=NOMe)Me	<i>t</i> -BuO	<i>d</i>	<i>d</i>	<i>d</i>	<i>d</i>

^aRelative yields determined from ¹H NMR analysis of the complete decomposition of 0.5 mM of the OHPY donor in 10% DMSO-d₆, 10% D₂O, and 80% H₂O, phosphate buffer (0.25 M) containing 0.2 mM of the metal chelator, diethylenetriaminepentaacetic acid (DTPA), pH 7.4 at 37 °C under argon.

^bDetermined by UV-vis spectroscopy. ^cLess than 5% decomposition after 2 days.

^dNot Determined due to low solubility.

OHPY decomposition was also monitored by UV-vis spectroscopy to measure donor half-lives at pH 7.4 and 37 °C (Table 1). Based on the chemistry of related HNO donors,^{19,20} we propose that the first step of decomposition is deprotonation which leads to release of nitrosocarbonyl plus pyrazolone. If the barrier to dissociation from anionic

OHPY is very small, observed half-lives should correlate with donor pK_a and the pyrazolone leaving group.^{19,20} Pyrazolone **2a** ($R^1 = \text{Ph}$, $R^2 = (\text{C}(=\text{NOMe})\text{Me}$, $pK_a = 6$) is a better leaving group than pyrazolone **2b** ($R^1 = \text{Ph}$, $R^2 = \text{Me}$, $pK_a = 7.6$),¹⁹ consistent with the much shorter half-life for OHPY **1a** ($t_{1/2} = 25$ min) compared with **1b** (stable). Exchanging the R^1 group from phenyl to methyl (OHPY **1c** vs. **1d**) increases the half-life by a factor of two, consistent with that previously reported for analogous HAPY and NHPY donors.^{19,47} A comparison of the known pK_a values of the related compounds, $\text{PhC}(\text{O})\text{NHOH}$ (8.8) and $\text{PhOC}(\text{O})\text{NHOH}$ (10.0),⁴⁸ indicates that the pK_a of OHPY **1a** is likely lower than that of OHPY **1c**. Although these two donors have the same pyrazolone leaving group, the longer half-life for OHPY **1a** ($t_{1/2} = 25$ min) compared with **1c** ($t_{1/2} = 0.6$ min) suggests that the barrier to dissociation may also affect the observed half-lives. In the case of NHYP donors, the dissociation barrier was found to be strongly dependent on the R^3 group.⁴⁷ The origin and impact of the R^3 group on OHPY dissociation requires further investigation.

HNO generation was examined by gas chromatographic (GC) headspace analysis to quantify the amount of its dimerization product, N_2O , formed following decomposition of OHPY donors in pH 7.4 phosphate buffer solutions at 37 °C (Table 2). The amount of HNO release was measured relative to standard HNO donor, Angeli's salt. As expected, HNO yields from OHPY donors are consistent with the corresponding yields of pyrazolone **2** and carboxylic acid **4** observed under the same conditions.

Table 2. HNO yields for OHPY donors at different concentrations

OHPY	% HNO ^a		
	500 μ M	100 μ M	20 μ M
1a	70	75	91
1b	<i>b</i>	<i>b</i>	<i>b</i>
1c	20	29	41
1d	8	17	29
1e	<i>c</i>	26	35 ^d

^aHNO yields are measured after complete decomposition of the donor and are reported relative to the standard HNO donor, Angeli's salt, as determined by N₂O headspace analysis (SEM $\pm$ 5%; *n* = 3). ^bStable. ^cNot determined due to low solubility. ^d*t*_{1/2} = 3.2 min (measured using UV-vis spectroscopy).

The competition between nitrosocarbonyl hydrolysis to HNO (*Path A*) and pyrazolone trapping (*Path B*) depends on the relative concentration of pyrazolone. Lower concentrations of pyrazolone **2** following decomposition of lower concentrations of OHPY **1** will disfavor NHPY formation and correspondingly increase the yield of HNO. Determination of HNO yields at different concentrations of donors (Table 2), confirms that the yield of HNO is impacted as expected.

2.3. Mechanistic Studies

Our proposed mechanism for OHPY decomposition involves deprotonation followed by initial formation of a nitrosocarbonyl intermediate. Pyrazolone **2b** has recently been demonstrated to be an efficient trap for nitrosocarbonyls under physiological conditions.⁴⁷ To confirm the formation of nitrosocarbonyls upon OHPY decomposition, we incubated OHPY **1a** (0.5 mM) in presence of pyrazolone **2b** (0.5 mM) in pH 7.4 phosphate buffer at 37 °C (Scheme 4). Upon decomposition of donor **1a** under

these conditions, we observe quantitative formation of NHPY **3b** (Supporting Information), strong evidence for nitrosocarbonyl formation.

Scheme 4. Reactivity of OHPY **1a** in the presence of pyrazolone **2b**

In the absence of pyrazolone **2b**, the decomposition of OHPY **1a** provides NHPY **3a** (26%) (which has a half-life of 5 days), and HNO (70%) and acetate (73%) (Scheme 4 and Tables 1, 2). The stability of NHPY **3a**, along with the observation that it is not formed in the presence of pyrazolone **2b**, also argues against the possibility of a direct intramolecular rearrangement from anionic OHPY **1a** to NHPY **3a** without involvement of a nitrosocarbonyl intermediate.

Based on reactivity studies of *bis*-heteroatom-substituted amides,⁴⁹ the formation of NHPY **3b** may be possible through the direct attack of pyrazolone **2b** on the amide nitrogen of the hydroxamic acid moiety of NHPY **3a** (Scheme 5). To examine this possibility, NHPY **3a** was incubated with pyrazolone **2b** and its stability was confirmed by ¹H NMR spectroscopy at pH 7.4 and 10. The p*K*_a of NHPY **3a** has recently been

measured to be 10.0 and its stability at or above pH 10 suggests a relatively high barrier for nitrosocarbonyl formation from this NHPY donor even when deprotonated.⁴⁷

Scheme 5. The possible reaction of NHPY **3a** with pyrazolone **2b**

3. Conclusions

The OHPY class of nitrosocarbonyl precursors efficiently generates these intermediates under physiological conditions following deprotonation and loss of pyrazolone. The nitrosocarbonyl produced is subsequently hydrolyzed to HNO in competition with trapping by the pyrazolone byproduct via an *N*-selective nitrosocarbonyl aldol reaction to form an isomeric NHPY compound. The rate of nitrosocarbonyl release from OHPY compounds in aqueous solution is dependent on the pyrazolone leaving group. This rate is also influenced by the R³ substituent, an effect that is under current investigation.

4. Experimental Section

4.1. Method and Materials

All starting materials were of reagent grade and used without further purification. *N*-hydroxy-*N*-(4-(acetyl-*O*-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)-*N*-acetamide (NHPY **3a**), *N*-hydroxy-*N*-(4-(acetyl-*O*-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)-*N*-methylcarbamate (NHPY **3c**), *N*-hydroxy-*N*-(4-(acetyl-*O*-methoxyoxime)-1,3-dimethyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)-*N*-methylcarbamate (NHPY **3d**),⁴⁷ 4-(acetyl-*O*-methoxyoxime)-3-methyl-1-phenyl-pyrazolone **2a**, 3,4-dimethyl-1-phenyl-pyrazolone **2b**, 4-(acetyl-*O*-methoxyoxime)-1,3-dimethylpyrazolone **2c**,¹⁹ 4-(acetyl-*O*-methoxyoxime)-4-bromo-3-methyl-1-phenyl-pyrazolone, 4-bromo-3,4-dimethyl-1-phenyl-pyrazolone, 4-(acetyl-*O*-methoxyoxime)-4-bromo-1,3-dimethyl-pyrazolone,¹⁸ *C*-methoxycarbohydroxamic acid, and *tert*-butylhydroxycarbamate⁵⁰ were prepared according to literature procedures. Acetohydroxamic acid was purchased and used without further purification. NMR spectra were obtained on a 400 MHz FT-NMR spectrometer. All chemical shifts are reported in parts per million (ppm) relative to residual CHCl₃ (7.26 ppm for ¹H, 77.23 ppm for ¹³C). High-resolution mass spectra were collected on a magnetic sector mass spectrometer working in fast atom bombardment (FAB) mode. Gas chromatography (GC) headspace analysis was performed on the instrument equipped with ECD detection and a molecular sieve packed column. Ultraviolet-Visible (UV-vis) absorption spectra were collected using a diode array spectrophotometer.

4.2. Synthesis

General procedure for the synthesis of N-((4-(acetyl-O-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)oxy)-acetamide (OHPY 1a) and N-((3,4-dimethyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)oxy)-acetamide (OHPY 1b): To a solution of acetohydroxamic acid (1 mmol) in dimethylformamide (3 mL) at room temperature was added sodium hydride, 60 % (1.1 mmol), and the reaction stirred for one hour. This solution was added to a solution of 1 mmol of brominated pyrazolone (4-(acetyl-O-methoxyoxime)-4-bromo-3-methyl-1-phenyl-pyrazolone for the synthesis of OHPY 1a and 4-bromo-3,4-dimethyl-1-phenyl-pyrazolone for the synthesis of OHPY 1b) in dimethylformamide (2 mL), and the reaction proceeded at room temperature for 3 hours. The reaction was diluted with ether (20 mL) and washed with ammonium chloride, water, and brine. The organic phase was collected, dried over magnesium sulphate (MgSO₄), and concentrated *in vacuo*. Recrystallization from dichloromethane and hexane gave the product OHPY 1a (25% yield) and, following purification by flash chromatography (30% ethylacetate/hexane) on silica gel, OHPY 1b (28% yield).

General procedure for the synthesis of N-((4-(acetyl-O-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)oxy)-methylcarbamate (OHPY 1c), N-((4-(acetyl-O-methoxyoxime)-1,3-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)oxy)-methylcarbamate (OHPY 1d), and N-(4-(acetyl-O-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)oxy)-tert-butylcarbamate (OHPY 1e): To a solution of 1 mmol of hydroxamic acid (C-methoxycarbohydroxamic acid for the synthesis OHPY 1c and 1d, and *tert*-butylhydroxycarbamate for the synthesis of OHPY 1e) in acetonitrile (3 mL) at room temperature was added triethylamine (1 mmol), and the

reaction stirred for one hour. This solution was added to a solution of 1 mmol of brominated pyrazolone 4-(acetyl-*O*-methoxyoxime)-4-bromo-3-methyl-1-phenyl-pyrazolone for the synthesis of OHPY **1c** and **1e**, and 4-(acetyl-*O*-methoxyoxime)-4-bromo-1,3-dimethyl-pyrazolone for the synthesis of OHPY **1d**) in acetonitrile (2 mL), and the reaction proceeded at room temperature for 3 hours. The reaction mixture was concentrated via rotary evaporation, redissolved in dichloromethane, and washed with water and brine. The organic phase was collected, dried over MgSO₄, and concentrated *in vacuo*. The compound was purified by flash chromatography (20% ethylacetate/hexane) on silica gel to give OHPY **1c**, **1d**, and **1e** with yields of 34%, 28%, and 37%, respectively.

Synthesis of N-hydroxy-N-(3,4-dimethyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-N-acetamide (NHPY 3b): To a solution of acetohydroxamic acid (210 mg, 2.80 mmol) and pyrazolone **2b** (105 mg, 0.56 mmol) in 50% aqueous ethanol (7 mL), was added potassium carbonate (12 mg, 0.09 mmol) to adjust the pH to 7-8. Sodium periodate (599 mg, 2.80 mmol) was added to the reaction mixture, which was sonicated for 10 min, and then stirred for 3 h at room temperature. The reaction mixture was diluted with ethanol (12 mL) and the solid was filtered. The filtrate was concentrated via rotary evaporation and the resulting solid was redissolved in ethylacetate (50 mL) and washed three times with a saturated solution of ammonium chloride (30 mL). The organic phase was collected, dried over MgSO₄, and concentrated *in vacuo*. Recrystallization from dichloromethane and hexane gave the title compound (73% yield).

4.3. Compound Characterization

***N*-((4-(Acetyl-*O*-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)-acetamide (OHPY 1a):** Colorless crystals, m.p. 143-145 °C; ¹H NMR (400 MHz, CDCl₃) δ: 8.96 (1H, s, OH), 7.85-7.83 (2H, m, arom), 7.41-7.38 (2H, m, arom), 7.22-7.20 (1H, m, arom), 3.90 (3H, s, Me), 2.34 (3H, s, Me), 2.06 (3H, s, Me), 1.92 (3H, s, Me). ¹³C NMR (100 MHz, CDCl₃) δ : 167.5, 158.1, 156.7, 150.8, 137.8, 129.1, 125.7, 119.1, 90.2, 62.5, 20.0, 16.4, 10.2. HR-MS (FAB): found *m/z* = 319.14094 (MH⁺); calc. for C₁₅H₁₉N₄O₄: 319.14063.

***N*-((3,4-Dimethyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)-acetamide (OHPY 1b):** White solid, m.p. 142-144 °C; ¹H NMR (400 MHz, CDCl₃) δ: 9.07 (1H, s, OH), 7.90-7.88 (2H, m, arom), 7.44-7.41 (2H, m, arom), 7.23-7.25 (1H, m, arom), 2.34 (3H, s, Me), 1.92 (3H, s, Me), 1.56 (3H, s, Me). ¹³C NMR (100 MHz, CDCl₃) δ : 170.6, 161.3, 158.1, 137.5, 132.1, 129.1, 125.6, 118.4, 87.6, 20.4, 18.5, 13.2. HR-MS (FAB): found *m/z* = 262.11949 (MH⁺); calc. for C₁₃H₁₅N₃O₃: 262.11917.

***N*-((4-(Acetyl-*O*-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)-methylcarbamate (OHPY 1c):** White solid, m.p. 128-130 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.92-7.90 (2H, m, arom), 7.50 (1H, s, OH), 7.41-7.44 (2H, m, arom), 7.20-7.22 (1H, m, arom), 3.90 (3H, s, Me), 3.77 (3H, s, Me), 2.38 (3H, s, Me), 2.08 (3H, s, Me). ¹³C NMR (100 MHz, CDCl₃) δ: 166.8, 158.8, 157.3, 151.3, 137.4, 129.2, 125.3, 118.7, 89.8, 62.8, 53.8, 14.9, 10.0. HR-MS (FAB): found *m/z* = 335.13496

(MH⁺); calc. for C₁₅H₁₉N₄O₅ : 335.13554.

***N*-((4-(Acetyl-*O*-methoxyoxime)-1,3-dimethyl-5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)-methylcarbamate (OHPY 1d):** White solid; ¹H NMR (400 MHz, CDCl₃) δ : 7.52 (1H, s, OH), 3.89 (3H, s, Me), 3.79 (3H, s, Me), 3.28 (3H, s, Me), 2.27 (3H, s, Me), 2.03 (3H, s, Me). ¹³C NMR (100 MHz, CDCl₃) δ: 168.6, 158.3, 157.6, 151.1, 88.9, 62.5, 53.3, 31.4, 15.0, 10.3. HR-MS (FAB): found *m/z* = 273.12013 (MH⁺); calc. for C₁₀H₁₇N₄O₅ : 273.11989.

***N*-((4-(Acetyl-*O*-methoxyoxime)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)oxy)-*tert*-butylcarbamate (OHPY 1e):** White solid, m.p. 102-104 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.94-7.92 (2H, m, arom), 7.43-7.40 (2H, m, arom), 7.31 (1H, s, OH), 7.23-7.21 (1H, m, arom), 3.91 (3H, s, Me), 2.36 (3H, s, Me), 2.06 (3H, s, Me), 1.46 (1H, s, C(Me)₃). ¹³C NMR (100 MHz, CDCl₃) δ: 167.3, 159.4, 156.1, 151.2, 137.8, 129.2, 125.3, 118.4, 89.8, 82.9, 62.4, 28.0, 15.1, 10.2. HR-MS (FAB): found *m/z* = 377.18180 (MH⁺); calc. for C₁₈H₂₅N₄O₅ : 377.18250.

***N*-Hydroxy-*N*-(3,4-dimethyl-5-oxo-1-phenyl-4,5-dihydro-1*H*-pyrazol-4-yl)-*N*-acetamide (NHPY 3b):** White solid; ¹H NMR (400 MHz, CDCl₃) δ: 9.08 (1H, s, OH), 7.87-7.85 (2H, m, arom), 7.45-7.43 (2H, m, arom), 7.24-7.22 (1H, m, arom), 2.18 (3H, s, Me), 2.10 (3H, s, Me), 1.68 (3H, s, Me). ¹³C NMR (100 MHz, CDCl₃) δ: 167.8, 159.0, 157.2, 151.4, 137.5, 127.9, 125.8, 119.5, 72.3, 22.5, 19.2, 12.4. HR-MS (FAB): found *m/z* = 262.11917 (MH⁺); calc. for C₁₃H₁₅N₃O₃: 262.11981.

Acknowledgments

We gratefully acknowledge the National Science Foundation (CHE-1213438) and Cardioxyl Pharmaceuticals for generous support of this research. We also thank the Johns Hopkins Department of Chemistry Facility Managers, Dr. Maxime A. Siegler (X-ray Crystallography), and Dr. I. Phil Mortimer (Mass Spectrometry) for assistance with compound identification and characterization.

Supplementary Material

Crystallographic data of OHPY **1a** (CCDC 1495947) and NHPY **3b** (CCDC 1495948) have been deposited at the Cambridge Crystallographic Database Centre. These data can be obtained for free via <https://www.ccdc.cam.ac.uk/>. Supplementary data associated with this article can be found in the online version, at <http://dx.doi.org/>

Notes

The authors declare the following competing financial interest(s): J.P.T. was a co-founder, stockholder, and served on the Scientific Advisory Board of Cardioxyl Pharmaceuticals.

References

1. Paolocci, N.; Saavedra, W. F.; Miranda, K. M.; Martignani, C.; Isoda, T.; Hare, J. M.; Espey, M. G.; Fukuto, J. M.; Feelisch, M.; Wink, D. A.; Kass, D. A. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 10463–10468.
2. Paolocci, N.; Katori, T.; Champion, H. C.; St. John, M. E.; Miranda, K. M.; Fukuto, J. M.; Wink, D. A.; Kass, D. A. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 5537–5542.
3. Dai, T.; Tian, Y.; Tocchetti, C. G.; Katori, T.; Murphy, A. M.; Kass, D. A.; Paolocci, N.; Gao, W. D. *J. Physiol.* **2007**, *580*, 951–960.
4. Tocchetti, C. G.; Wang, W.; Froehlich, J. P.; Huke, S.; Aon, M. A.; Wilson, G. M.; Di Benedetto, G.; O'Rourke, B.; Gao, W. D.; Wink, D. A.; Toscano, J. P.; Zaccolo, M.; Bers, D. M.; Valdivia, H. H.; Cheng, H.; Kass, D. A.; Paolocci, N. *Circ. Res.* **2007**, *100*, 96–104.
5. Tocchetti, C. G.; Stanley, B. A.; Murray, C. I.; Sivakumaran, V.; Donzelli, S.; Mancardi, D.; Pagliaro, P.; Gao, W. D.; van Eyk, J.; Kass, D. A.; Wink, D. A.; Paolocci, N. *Antioxid. Redox Signal.* **2011**, *14*, 1687–1698.
6. Kemp-Harper, B. K. *Antioxid. Redox Signal.* **2011**, *14*, 1609–1616.
7. Flores-Santana, W.; Salmon, D. J.; Donzelli, S.; Switzer, C. H.; Basudhar, D.; Ridnour, L.; Cheng, R.; Glynn, S. A.; Paolocci, N.; Fukuto, J. M.; Miranda, K. M.; Wink, D. A. *Antioxid. Redox Signal.* **2011**, *14*, 1659–1674.
8. Sabbah, H. N.; Tocchetti, C. G.; Wang, M.; Daya, S.; Gupta, R. C.; Tunin, R. S.; Mazhari, R.; Takimoto, E.; Paolocci, N.; Cowart, D.; Colucci, W. S.; Kass, D. A. *Circ. Hear. Fail.* **2013**, *6*, 1250–1258.
9. Arcaro, A.; Lembo, G.; Tocchetti, C. G. *Curr. Heart Fail. Rep.* **2014**, *11*, 227–235.
10. Shafirovich, V.; Lyman, S. V. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 7340–7345.
11. Hughes, M. N.; Cammack, R. *Methods Enzymol.* **1999**, *301*, 279–287.
12. Porcheddu, A.; De Luca, L.; Giacomelli, G. *Synlett* **2009**, *13*, 2149–2153.
13. Sirsalmath, K.; Suárez, S. A.; Bikiel, D. E.; Doctorovich, F. *J. Inorg. Biochem.* **2013**, *118*, 134–139.

14. Toscano, J. P.; Brokkfield, F. A.; Cohen, A. D.; Courtney, S. M.; Frost, L. M.; Kalish, V. J. U.S. Patent 8,030,356, 2011.
15. Sutton, A. D.; Williamson, M.; Weismiller, H.; Toscano, J. P. *Org. Lett.* **2012**, *14*, 472–475.
16. Sha, X.; Isbell, T. S.; Patel, R. P.; Day, C. S.; King, S. B. *J. Am. Chem. Soc.* **2006**, *128*, 9687–9692.
17. Shoman, M. E.; DuMond, J. F.; Isbell, T. S.; Crawford, J. H.; Brandon, A.; Honovar, J.; Vitturi, D. A.; White, C. R.; Patel, R. P.; King, S. B. *J. Med. Chem.* **2011**, *54*, 1059–1070.
18. Guthrie, D. A.; Kim, N. Y.; Siegler, M. A.; Moore, C. D.; Toscano, J. P. *J. Am. Chem. Soc.* **2012**, *134*, 1962–1965.
19. Guthrie, D. A.; Ho, A.; Takahashi, C. G.; Collins, A.; Morris, M.; Toscano, J. P. *J. Org. Chem.* **2015**, *80*, 1338–1348.
20. Guthrie, D. A.; Nourian, S.; Takahashi, C. G.; Toscano, J. P. *J. Org. Chem.* **2015**, *80*, 1349–1356.
21. Atkinson, R. N.; Storey, B. M.; King, S. B. *Tetrahedron Lett.* **1996**, *37*, 9287–9290.
22. Miao, Z.; King, B. *Nitric Oxide* **2016**, *57*, 1–14.
23. Kirby G. W., Sweeny J. G. *J. Chem. Soc. Perkin Trans. I.* **1981**, 3250–3254.
24. Corrie J. E. T., Kirby G. W., Mackinnon J. W. M. *J. Chem. Soc. Perkin Trans. I.* **1985**, 883–886.
25. Zeng, B; Huang, J.; Wright, M. W.; King, S. B. *Bioorg. Med. Chem.* **2004**, *14*, 5565–5568.
26. Quadrelli, P.; Mella, M.; Caramella, P. *Tetrahedron Lett.* **1999**, *40*, 797–800.
27. O'Bannon, P. E.; William, D. P. *Tetrahedron Lett.* **1988**, *29*, 5719–5722.
28. Evans, A. S; Cohen, A. D.; Gurard-Levin, Z. A.; Kebede, N.; Celius T. C.; Miceli, A. P.; Toscano, J. P. *Can. J. Chem.* **2011**, *89*, 130–138.
29. Frazier, C. P.; Engelking, J. R.; Read de Alaniz, J. *J. Am. Chem. Soc.* **2011**, *133*, 10430–10433.
30. Fakhruddin, A.; Iwasa, S.; Nishiyama, H.; Tsutsumi, K. *Tetrahedron Lett.* **2004**, *45*, 9323–9326.

31. Yamamoto, Y.; Yamamoto, H. *European J. Org. Chem.* **2006**, 2006, 2031–2043.
32. Chaiyaveij, D.; Cleary, L.; Batsanov, A. S.; Marder, T. B.; Shea, K. J.; Whiting, A. *Org. Lett.* **2011**, 13, 3442–3445.
33. Sandoval, D.; Frazier, C. P.; Bugarin, A.; Read de Alaniz, J. *J. Am. Chem. Soc.* **2012**, 134, 18948–18951.
34. Baidya, M.; Griffin, K. A.; Yamamoto, H. *J. Am. Chem. Soc.* **2012**, 134, 18566–18569.
35. Selig, P. *Angew. Chemie Int. Ed.* **2013**, 52, 7080–7082.
36. Palmer, L.; Frazier, C.; Read de Alaniz, J. *Synthesis*. **2013**, 46, 269–280.
37. Baidya, M.; Yamamoto, H. *Synthesis*. **2013**, 45, 1931–1938.
38. Frazier, C. P.; Sandoval, D.; Palmer, L. I.; Read de Alaniz, J. *Chem. Sci.* **2013**, 4, 3857–3862.
39. Yang, W.; Huang, L.; Yu, Y.; Pflasterer, D.; Rominger, F.; Hashmi, S. K. *Chem. Eur. J.* **2014**, 20, 3927–3931.
40. Yu, C.; Song, A.; Zhang, F. Wang, W. *ChemCatChem*. **2014**, 6, 1863–1865.
41. Sandoval, D.; Samoshin, A. V.; Read de Alaniz, J. *Org. Lett.* **2015**, 17, 4514–4517.
42. Ramakrishna, I.; Grandhi, G. S.; Sahoo, H.; Baidya, M. *Chem. Commun.* **2015**, 51, 13976–13979.
43. Maji, B.; Yamamoto, H. *Angew. Chem.* **2014**, 126, 14700–14703.
44. Maji, B.; Yamamoto, H. *Bull. Chem. Soc. Jpn.* **2015**, 88, 753–762.
45. Xu, C.; Zhang, L.; Luo, S. *Angew. Chem. Int. Ed.* **2014**, 53, 4149–4153.
46. Merino, P.; Tejero, T.; Delso, I.; Matute, R. *Synthesis* **2016**, 48, 653–676.
47. Nourian, S.; Zilber, Z. A.; Toscano, J. P. “Development of *N*-Substituted Hydroxamic Acids with Pyrazolone Leaving Groups as Nitrosocarbonyl Precursors”, *manuscript under review*.
48. Steinberg, G. M.; Bolger, J. *J. Org. Chem.* **1956**, 21, 660–662.
49. Glover, S. A. In *The Chemistry of Hydroxylamines, Oximes, and Hydroxamic Acids, Part 2*; Rappoport, Z., Liebman, J. F., Eds.; John Wiley & Sons: Chichester, West Sussex, 2009, p 839–923.

50. Defoin, A.; Fritz, H.; Schmidlin, C.; Streith, J. *Helv. Chim. Acta* **1987**, *70*, 554–569.

Graphical Abstract